MaaT Pharma (MAAT) AI Stock Analysis

• Market Cap: €67.01M
• Dividend Yield: N/A
• Average Volume (3M): 74.34K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.55
• Revenue Growth: 52.55%
• EPS Growth: -5.97%
• Country: FR
• Employees: 59
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.00
• Shares Outstanding: 16,135,971
• 10 Day Avg. Volume: 95,157
• 30 Day Avg. Volume: 74,345
• PEG Ratio: -0.13
• Price to Book (P/B): 10.06
• Price to Sales (P/S): 32.34
• P/FCF Ratio: -4.56
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €17.00
• Price Target Upside: 291.71% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 48 Neutral
• Price Target: €5.50 ▲(26.73% Upside)

MaaT Pharma's overall stock score reflects significant financial challenges, with ongoing losses and high leverage being the most impactful factors. Technical analysis provides a neutral outlook, while valuation remains difficult due to negative earnings. The absence of earnings call and corporate events data limits further insights.

Positive Factors

Revenue Growth

Strong revenue growth indicates successful market penetration and increasing demand for MaaT Pharma's microbiome-based therapies, supporting long-term business sustainability.

Product Innovation

Specialization in innovative microbiome therapies positions MaaT Pharma as a leader in a niche market, potentially offering competitive advantages and long-term growth opportunities.

Gross Profit Margin

A strong gross profit margin suggests operational efficiency in production, which can contribute to improved profitability as the company scales.

Negative Factors

High Leverage

High leverage can increase financial risk, limiting flexibility and potentially impacting the company's ability to invest in growth or weather economic downturns.

Operating Losses

Continued operating losses indicate challenges in achieving profitability, which can hinder long-term financial stability and investor confidence.

Negative Cash Flow

Negative cash flow suggests difficulties in covering operational expenses, which may require additional financing and could impact the company's ability to sustain operations.

MaaT Pharma Business Overview & Revenue Model

Company Description

MaaT Pharma SA, a clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors. Its products pipeline includes MaaT013 that has completed phase 2 clinical trials for the treatment of acute graft versus host diseases, as well as in preclinical trials to treat melanoma; MaaT033, which is in phase 1b clinical trials for the improvement of survival in patients with acute myeloid leukemia or other liquid tumors receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors. The company was incorporated in 2014 and is headquartered in Lyon, France.

How the Company Makes Money

MaaT Pharma makes money primarily through the development and commercialization of its microbiome-based therapeutics. The company generates revenue from licensing agreements, research collaborations, and milestone payments with pharmaceutical companies and research institutions. Additionally, MaaT Pharma may earn income from grants and funding related to its research and development activities. Key partnerships with academic and commercial entities contribute to its earnings by facilitating the advancement and potential market introduction of its therapeutic products.

MaaT Pharma Financial Statement Overview

Summary

MaaT Pharma is experiencing financial difficulties typical of biotech firms, with ongoing losses and high leverage. Despite revenue growth, the company faces significant operating losses and negative cash flows, with a high debt-to-equity ratio and negative net profit margins.

Income Statement

MaaT Pharma has shown revenue growth over the years, with a 44.36% increase from 2023 to 2024. However, the company is still operating at a loss, with a negative net profit margin of -898.45% in 2024. The gross profit margin in 2024 was 61.13%, indicating some efficiency in covering the cost of goods sold. EBIT and EBITDA margins remain negative, reflecting significant operating losses.

Balance Sheet

The company's balance sheet reveals a high debt-to-equity ratio of 1.54 in 2024, suggesting high leverage. The equity ratio decreased to 26.84%, indicating a decline in equity relative to total assets. Return on equity remains negative due to continued net losses, highlighting profitability challenges.

Cash Flow

Operating cash flow is negative and worsening, with a free cash flow of -22.79 million in 2024. The operating cash flow to net income ratio is 0.76, indicating cash flow issues in supporting net losses. The free cash flow to net income ratio is 0.79, suggesting limited free cash available relative to net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.92M	3.22M	2.23M	1.43M	972.00K	0.00
Gross Profit	1.56M	1.97M	784.00K	1.09M	806.00K	-164.00K
EBITDA	-31.11M	-26.34M	-22.07M	-13.10M	-8.57M	-6.58M
Net Income	-31.13M	-28.90M	-19.72M	-13.71M	-9.02M	-5.35M
Balance Sheet
Total Assets	48.88M	38.50M	42.93M	44.73M	49.42M	24.28M
Cash, Cash Equivalents and Short-Term Investments	15.04M	20.22M	24.31M	35.31M	43.30M	19.91M
Total Debt	14.40M	15.96M	14.07M	11.36M	5.81M	6.08M
Total Liabilities	40.58M	28.16M	22.46M	17.91M	9.56M	8.34M
Stockholders Equity	8.29M	10.34M	20.47M	26.81M	39.86M	15.94M
Cash Flow
Free Cash Flow	-25.58M	-22.79M	-19.76M	-13.27M	-8.17M	-6.13M
Operating Cash Flow	-24.80M	-22.04M	-18.67M	-12.61M	-7.93M	-5.81M
Investing Cash Flow	-820.00K	-416.00K	-440.00K	-815.00K	-238.00K	-523.00K
Financing Cash Flow	9.51M	18.33M	8.14M	5.36M	31.56M	20.84M

MaaT Pharma Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 4.34
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:MAAT, the sentiment is Neutral. The current price of 4.34 is above the 20-day moving average (MA) of 4.04, below the 50-day MA of 4.75, and below the 200-day MA of 5.80, indicating a neutral trend. The MACD of -0.17 indicates Negative momentum. The RSI at 52.04 is Neutral, neither overbought nor oversold. The STOCH value of 69.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FR:MAAT.

MaaT Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
OSE	70 Outperform	€161.50M	4.07	58.68%	―	3037.72%	―
TNG	55 Neutral	€149.61M	-4.06	-223.43%	―	111.76%	-22.45%
ABNX	52 Neutral	€119.01M	-25.90	-59.27%	―	-10.91%	-25.57%
ALCLS	51 Neutral	€200.42M	-5.60	-60.75%	―	327.14%	49.02%
ALSEN	49 Neutral	€110.02M	-3.91	-36.00%	―	―	10.87%
MAAT	48 Neutral	€67.01M	―	―	―	52.55%	-5.97%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%